The Blavatnik Biomedical Accelerator at Harvard University provides strategic, financial, and advisory support for well-defined, faculty-led R&D projects selected for their clear commercial potential. By fueling translational research, the Blavatnik Biomedical Accelerator enables members of Harvard’s research community to develop a shared vision with partners in industry, ensuring that lifesaving technologies have the opportunities and resources to reach the public.
This video created by the Blavatnik Family Foundation demonstrates how the targeted funding and strategic advising of the Blavatnik Biomedical Accelerator at Harvard University is helping scientists to understand disease and advance new treatments that may save lives.
The primary goal of the Blavatnik Biomedical Accelerator is to advance Harvard’s breakthrough discoveries to a value inflection point where an industry partnership can commence. Every Blavatnik Biomedical Accelerator project receives strategic and financial support to advance it on a trajectory toward a crucial milestone, whether that is the validation of initial observations, achievement of proof of concept in disease models, further optimization of therapeutic leads, or, in the case of a platform technology, demonstration of a targeted application. Through this program, Harvard’s most commercially promising biomedical discoveries are developed into robust intellectual property positions. Because selected projects are vetted by an advisory committee of highly qualified and widely respected industry experts, these projects present attractive opportunities for collaborations, partnerships, and startups.